Logo Prima Biomed
Products
Dedicated to leveraging its current technology to develop innovative treatment

Manufacturing of CVac™

 Lightbox

CVac™

CVac therapy is a personalized immunocellular therapeutic that has been investigated for the treatment of epithelial cancer.

 

It has been partnered with US based biotechnology company Sydys Corporation. Sydys is continuing its clinical development and further information can be found at www.sydyscorp.com.

 

Prior to out-licensing to Sydys, Prima completed Phase IIb studies in ovarian cancer and developed considerable expertize in an automated manufacturing platform. Briefly, the CVac treatment stimulates the patient‘s own immune system to target and destroy tumors.

The product is manufactured and customized for each patient individually.

The patient‘s own immune precursor cells are isolated from their blood by a process called leukapheresis. These cells are matured in the laboratory and treated with a tumor-specific cell surface protein called mucin 1. The unique form of mucin 1 is present in great amounts on epithelial tumors, thus it is a specific antigen and a favorable target for a cancer therapy.
The dendritic cells process the mucin 1 antigen and are then frozen for later shipment to the physician for administration to the patient.

At the clinic, CVac is thawed and injected intradermally (under the surface of the skin).

CVac then moves through the patient’s blood stream, and as CVac comes in contact with T cells, it activates them to recognize and subsequently destroy tumor cells expressing the tumor form of mucin 1 protein.



Completed CVac™ Clinical Trials

Product Phase Protocol Population Patients Status

CVac

I

CAN-001

Terminal adenocarcinoma (breast, ovarian, fallopian tube, colon, lung, esophageal)

10 Completed

CVac

II

CAN-002

Ovarian cancer patients with no further treatment options

28 Completed

CVac

II

CAN-003x

Ovarian cancer patients who have progressed on CAN-003

9 Completed

CVac

II

CAN-003

Ovarian cancer patients in remission after first or second line therapy

63 Completed

CVac

IIb

CAN-004 (A)

Ovarian cancer patients in remission after 1st line surgery and chemotherapy

76 Recruitment completed

CVac

IIb

CAN-004 (B)

Ovarian cancer patients in remission after 2nd line surgery and chemotherapy

~210 Recruitment ceased